TG Therapeutics TGTX shares soared 10.2% in the last trading session to close at $40.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 20.6% gain over the past four weeks.

This rise in share price is likely due to positive investor sentiments around TG Therapeutics’ sole marketed product Briumvi, which is approved in multiple sclerosis indication. Earlier this month, the company reported full year 2024 results where Briumvi product sales surged more than 200% year-over-year to $313 million. Based on this encouraging sales growth, the company is targeting $540 million from the drug’s sales this year.

This biopharmaceutical company is expected to post quarterly earnings of $0.19 per share in its upcoming report, which represents a year-over-year change of +371.4%. Revenues are expected to be $117.83 million, up 85.6% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For TG Therapeutics, the consensus EPS estimate for the quarter has been revised 127.5% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TGTX going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

TG Therapeutics is part of the Zacks Medical - Biomedical and Genetics industry. Cue Biopharma, Inc. CUE, another stock in the same industry, closed the last trading session 1.8% lower at $0.96. CUE has returned -31.4% in the past month.

For Cue Biopharma , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.16. This represents a change of +42.9% from what the company reported a year ago. Cue Biopharma currently has a Zacks Rank of #3 (Hold).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

TG Therapeutics, Inc. (TGTX) : Free Stock Analysis Report

Cue Biopharma, Inc. (CUE) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research